Abstract
Background: Oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreduction surgery (CRS) in peritoneal metastasis (PM) of colorectal origin did not show any survival benefit in PRODIGE-7 trial and additional value of other regimen-based HIPEC is under debate. However, centralization has been shown to improve post-operative mortality (POM) in CRS and HIPEC for PM of various origins. We aimed to evaluate the impact of centralization on POM after CRS alone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
